サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
市場調査レポート
商品コード
1678517

抗体薬物複合体受託製造の世界市場：市場規模・シェア・動向分析 (リンカー別・症状別・地域別)、セグメント別予測 (2025年～2030年)

Antibody Drug Conjugates Contract Manufacturing Market Size, Share & Trends Analysis Report By Linker (Cleavable, Non-cleavable), By Condition (Myeloma, Lymphoma, Breast Cancer), By Region, And Segment Forecasts, 2025 - 2030

出版日
ページ情報
英文 100 Pages
納期
2～10営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.06円
抗体薬物複合体受託製造の世界市場：市場規模・シェア・動向分析 (リンカー別・症状別・地域別)、セグメント別予測 (2025年～2030年)
出版日: 2025年02月04日
発行: Grand View Research
ページ情報: 英文 100 Pages
納期: 2～10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

抗体薬物複合体受託製造市場の成長と動向：

Grand View Research, Inc.の最新レポートによると、世界の抗体薬物複合体受託製造の市場規模は、2025年から2030年にかけて10.99%のCAGRを記録し、2030年までに165億5,000万米ドルに達する見込みです。

業界の成長を促進する要因としては、受託製造の需要に寄与する抗体薬物複合体 (ADC) の複雑な性質、抗体治療に関する研究の増加、がん罹患率の上昇などが挙げられます。パンデミックの間、がんの臨床試験は短期間中止されました。しかし、病気の深刻さのため、臨床試験は再び開始されました。IQVIA Oncology Trends Report 2022によると、がんの臨床試験数は増加しています。

IQVIAのレポートによると、2016年から2021年の間に腫瘍学の臨床試験は56％増加しました。この臨床試験数は、世界のがんの有病率の増加により、さらに増加すると予想されます。これはADCの開発と製造活動を支援し、パンデミック後の業界の成長を支えるものと期待されます。抗体薬物複合体は、がん細胞のみを標的とし、体内の健康な細胞には影響を与えないため、がんの治療において高い効率を発揮します。その結果、複数のバイオ医薬品企業がADC関連の研究に多額の資金援助を受けています。

例えば、2022年10月、マブリンク・バイオサイエンス社は、抗体薬物複合体のパイプラインを構築するため、シリーズA資金調達から3,100万米ドルを調達しました。このように、ADCの研究開発に対する多額の投資は、今後数年間でADCの可用性を向上させ、ADC受託製造の需要を支えることが期待されます。2021年9月、米国FDAはADC tisotumab vedotin-tftvについて、病勢進行または化学療法後の再発性または転移性子宮頸がん成人患者の治療に対する早期承認を与えました。このような承認は、今後数年間で、ADC受託製造サービスの需要を押し上げると予想されます。

抗体薬物複合体受託製造市場：分析概要

  • 症状別では、骨髄腫、リンパ腫、乳がん、その他が含まれます。骨髄腫セグメントは2024年に49.61%の最大収益シェアで市場をリードしました。リンパ腫セグメントは予測期間中に最も速いCAGRを示すと予測されています。
  • リンカー別に、市場は開裂性リンカーと非開裂性リンカーに区分されます。開裂性リンカーのセグメントは、2024年に56.1%の最大収益シェアで市場をリードしました。
  • 北米の抗体薬物複合体受託製造市場は、予測期間中に最も速いCAGRを記録する見込みです。
  • アジア太平洋地域の抗体薬物複合体受託製造市場は、2024年に40.93%の最大売上シェアで市場を独占しました。この地域の成長は主に、特にインドや中国などの国々における規制改革への支援と、低コストの労働力によるものです。

目次

第1章 分析方法・範囲

第2章 エグゼクティブサマリー

第3章 抗体薬物複合体 (ADC) 受託製造市場：変動要因・傾向・範囲

  • 市場連関の見通し
    • 親市場の見通し
    • 関連/付随市場の見通し
  • 市場力学
    • 市場促進要因の分析
    • 市場抑制要因の分析
  • 技術の情勢
  • 価格モデル分析
  • 業界エコシステム分析
  • 市場分析ツール
    • ポーターのファイブフォース分析
    • PESTEL分析
    • COVID-19の影響分析

第4章 抗体薬物複合体 (ADC) 受託製造市場：症状別の推定・動向分析

  • 抗体薬物複合体 (ADC) 受託製造市場、症状別：セグメントダッシュボード
  • 抗体薬物複合体 (ADC) 受託製造市場、症状別：変動分析
  • 状態別、2018年-2030年
  • 骨髄腫
  • リンパ腫
  • 乳がん
  • その他

第5章 抗体薬物複合体 (ADC) 受託製造市場：リンカー別の推定・動向分析

  • 抗体薬物複合体 (ADC) 受託製造市場、リンカー別：セグメントダッシュボード
  • 抗体薬物複合体 (ADC) 受託製造市場、リンカー別：変動分析
  • リンカー、2018年-2030年
  • 切断可能なリンカー
  • 切断不可能なリンカー

第6章 抗体薬物複合体 (ADC) 受託製造市場：地域別の推定・動向分析

  • 市場シェア分析：地域別 (2024年・2030年)
  • 市場ダッシュボード：地域別
  • 世界市場のスナップショット：地域別
  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • 英国
    • ドイツ
    • フランス
    • イタリア
    • スペイン
    • スウェーデン
    • デンマーク
    • ノルウェー
  • アジア太平洋
    • 日本
    • 中国
    • インド
    • タイ
    • 韓国
    • オーストラリア
  • ラテンアメリカ
    • ブラジル
    • アルゼンチン
  • 中東・アフリカ
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦
    • クウェート

第7章 競合情勢

  • 市場参入企業の分類
    • 市場リーダー
    • 新興企業
  • 企業別の市場シェア/評価分析（2024年）
  • 企業プロファイル
    • Sterling
    • Recipharm AB
    • Lonza
    • Catalent, Inc.
    • Sartorius AG
    • Wuxi Biologics
    • Samsung Biologics
    • Piramal Group（Piramal Pharma Solutions）
    • AbbVie, Inc.（AbbVie Contract Manufacturing）
    • Merck KGaA
図表

List of Tables

  • Table 1 Information Procurement
  • Table 2 Primary Research Pattern
  • Table 3 Market Research Approaches
  • Table 4 Value Chain-Based Sizing & Forecasting
  • Table 5 Market Formulation & Validation
  • Table 6 Antibody Drug Conjugates (ADC) Contract Manufacturing, Market Segmentation
  • Table 7 Market Driver Relevance Analysis (Current & Future Impact)
  • Table 8 Market Restraint Relevance Analysis (Current & Future Impact)
  • Table 9 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
  • Table 10 Porter's Five Forces Analysis
  • Table 11 Regional Marketplace: Key Takeaways
  • Table 12 Global Antibody Drug Conjugates (ADC) Contract Manufacturing, for Myeloma, 2018 - 2030 (USD Million)
  • Table 13 Global Antibody Drug Conjugates (ADC) Contract Manufacturing, for Lymphoma, 2018 - 2030 (USD Million)
  • Table 14 Global Antibody Drug Conjugates (ADC) Contract Manufacturing, for Breast Cancer, 2018 - 2030 (USD Million)
  • Table 15 Global Antibody Drug Conjugates (ADC) Contract Manufacturing, for Others, 2018 - 2030 (USD Million)
  • Table 16 Global Antibody Drug Conjugates (ADC) Contract Manufacturing, for Cleavable Linker, 2018 - 2030 (USD Million)
  • Table 17 Global Antibody Drug Conjugates (ADC) Contract Manufacturing, for Non-cleavable Linker, 2018 - 2030 (USD Million)
  • Table 18 Regional Outlook, 2024 & 2030
  • Table 19 North America Antibody Drug Conjugates (ADC) Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Table 20 U.S. Antibody Drug Conjugates (ADC) Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Table 21 Canada Antibody Drug Conjugates (ADC) Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Table 22 Mexico Antibody Drug Conjugates (ADC) Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Table 23 Europe Antibody Drug Conjugates (ADC) Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Table 24 UK Antibody Drug Conjugates (ADC) Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Table 25 Germany Antibody Drug Conjugates (ADC) Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Table 26 France Antibody Drug Conjugates (ADC) Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Table 27 Italy Antibody Drug Conjugates (ADC) Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Table 28 Spain Antibody Drug Conjugates (ADC) Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Table 29 Denmark Antibody Drug Conjugates (ADC) Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Table 30 Sweden Antibody Drug Conjugates (ADC) Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Table 31 Norway Antibody Drug Conjugates (ADC) Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Table 32 Asia Pacific Antibody Drug Conjugates (ADC) Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Table 33 India Antibody Drug Conjugates (ADC) Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Table 34 China Antibody Drug Conjugates (ADC) Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Table 35 Japan Antibody Drug Conjugates (ADC) Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Table 36 South Korea Antibody Drug Conjugates (ADC) Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Table 37 Australia Antibody Drug Conjugates (ADC) Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Table 38 Thailand Antibody Drug Conjugates (ADC) Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Table 39 Latin America Antibody Drug Conjugates (ADC) Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Table 40 Brazil Antibody Drug Conjugates (ADC) Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Table 41 Argentina Antibody Drug Conjugates (ADC) Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Table 42 MEA Antibody Drug Conjugates (ADC) Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Table 43 South Africa Antibody Drug Conjugates (ADC) Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Table 44 Saudi Arabia Antibody Drug Conjugates (ADC) Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Table 45 UAE Antibody Drug Conjugates (ADC) Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Table 46 Kuwait Antibody Drug Conjugates (ADC) Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 List of Secondary Sources
  • Fig. 2 List of Abbreviations
  • Fig. 3 Global Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Condition, 2018 - 2030 (USD Million)
  • Fig. 4 Global Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Linker, 2018 - 2030 (USD Million)
  • Fig. 5 Global Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Region, 2018 - 2030 (USD Million)
  • Fig. 6 North America Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Country, 2018 - 2030 (USD Million)
  • Fig. 7 North America Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Condition, 2018 - 2030 (USD Million)
  • Fig. 8 North America Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Linker, 2018 - 2030 (USD Million)
  • Fig. 9 U.S. Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Condition, 2018 - 2030 (USD Million)
  • Fig. 10 U.S. Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Linker, 2018 - 2030 (USD Million)
  • Fig. 11 Canada Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Condition, 2018 - 2030 (USD Million)
  • Fig. 12 Canada Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Linker, 2018 - 2030 (USD Million)
  • Fig. 13 Mexico Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Condition, 2018 - 2030 (USD Million)
  • Fig. 14 Mexico Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Linker, 2018 - 2030 (USD Million)
  • Fig. 15 Europe Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Country, 2018 - 2030 (USD Million)
  • Fig. 16 Europe Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Condition, 2018 - 2030 (USD Million)
  • Fig. 17 Europe Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Linker, 2018 - 2030 (USD Million)
  • Fig. 18 Germany Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Condition, 2018 - 2030 (USD Million)
  • Fig. 19 Germany Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Linker, 2018 - 2030 (USD Million)
  • Fig. 20 UK Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Condition, 2018 - 2030 (USD Million)
  • Fig. 21 UK Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Linker, 2018 - 2030 (USD Million)
  • Fig. 22 France Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Condition, 2018 - 2030 (USD Million)
  • Fig. 23 France Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Linker, 2018 - 2030 (USD Million)
  • Fig. 24 Italy Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Condition, 2018 - 2030 (USD Million)
  • Fig. 25 Italy Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Linker, 2018 - 2030 (USD Million)
  • Fig. 26 Spain Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Condition, 2018 - 2030 (USD Million)
  • Fig. 27 Spain Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Linker, 2018 - 2030 (USD Million)
  • Fig. 28 Denmark Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Condition, 2018 - 2030 (USD Million)
  • Fig. 29 Denmark Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Linker, 2018 - 2030 (USD Million)
  • Fig. 30 Sweden Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Condition, 2018 - 2030 (USD Million)
  • Fig. 31 Sweden Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Linker, 2018 - 2030 (USD Million)
  • Fig. 32 Norway Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Condition, 2018 - 2030 (USD Million)
  • Fig. 33 Norway Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Linker, 2018 - 2030 (USD Million)
  • Fig. 34 Asia Pacific Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Country, 2018 - 2030 (USD Million)
  • Fig. 35 Asia Pacific Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Condition, 2018 - 2030 (USD Million)
  • Fig. 36 Asia Pacific Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Linker, 2018 - 2030 (USD Million)
  • Fig. 37 China Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Condition, 2018 - 2030 (USD Million)
  • Fig. 38 China Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Linker, 2018 - 2030 (USD Million)
  • Fig. 39 Japan Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Condition, 2018 - 2030 (USD Million)
  • Fig. 40 Japan Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Linker, 2018 - 2030 (USD Million)
  • Fig. 41 India Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Condition, 2018 - 2030 (USD Million)
  • Fig. 42 India Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Linker, 2018 - 2030 (USD Million)
  • Fig. 43 South Korea Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Condition, 2018 - 2030 (USD Million)
  • Fig. 44 South Korea Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Linker, 2018 - 2030 (USD Million)
  • Fig. 45 Australia Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Condition, 2018 - 2030 (USD Million)
  • Fig. 46 Australia Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Linker, 2018 - 2030 (USD Million)
  • Fig. 47 Thailand Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Condition, 2018 - 2030 (USD Million)
  • Fig. 48 Thailand Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Linker, 2018 - 2030 (USD Million)
  • Fig. 49 Latin America Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Country, 2018 - 2030 (USD Million)
  • Fig. 50 Latin America Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Condition, 2018 - 2030 (USD Million)
  • Fig. 51 Latin America Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Linker, 2018 - 2030 (USD Million)
  • Fig. 52 Brazil Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Condition, 2018 - 2030 (USD Million)
  • Fig. 53 Brazil Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Linker, 2018 - 2030 (USD Million)
  • Fig. 54 Argentina Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Condition, 2018 - 2030 (USD Million)
  • Fig. 55 Argentina Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Linker, 2018 - 2030 (USD Million)
  • Fig. 56 Middle East & Africa Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Country, 2018 - 2030 (USD Million)
  • Fig. 57 Middle East & Africa Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Condition, 2018 - 2030 (USD Million)
  • Fig. 58 Middle East & Africa Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Linker, 2018 - 2030 (USD Million)
  • Fig. 59 South Africa Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Condition, 2018 - 2030 (USD Million)
  • Fig. 60 South Africa Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Linker, 2018 - 2030 (USD Million)
  • Fig. 61 Saudi Arabia Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Condition, 2018 - 2030 (USD Million)
  • Fig. 62 Saudi Arabia Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Linker, 2018 - 2030 (USD Million)
  • Fig. 63 UAE Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Condition, 2018 - 2030 (USD Million)
  • Fig. 64 UAE Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Linker, 2018 - 2030 (USD Million)
  • Fig. 65 Kuwait Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Condition, 2018 - 2030 (USD Million)
  • Fig. 66 Kuwait Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Linker, 2018 - 2030 (USD Million)
目次
Product Code: GVR-4-68039-623-5

Antibody Drug Conjugates Contract Manufacturing Market Growth & Trends:

The global antibody drug conjugates contract manufacturing market size is expected to reach USD 16.55 billion by 2030, registering a CAGR of 10.99% from 2025 to 2030, according to a new report by Grand View Research, Inc. The factors driving the industry growth include the complex nature of antibody drug conjugates (ADCs) contributing to the demand for contract manufacturing, the increasing number of research on antibody therapies, and the rise in cancer incidence. During the pandemic, the clinical trials for cancer were stopped for a short period. However, owing to the severity of the disease, the trials were started again. As per the IQVIA Oncology Trends Report 2022, the number of clinical trials for cancer is growing.

The IQVIA report states that there was a 56% increase in oncology clinical trials between 2016 and 2021. This number of clinical studies is expected to rise even further owing to the growing prevalence of cancer worldwide. This is expected to support the ADC development and manufacturing activities, thus supporting industry growth post-pandemic. Antibody drug conjugates have high efficiency in treating cancer as it only targets the cancerous cells and does not affect the healthy cells of the body. As a result, several biopharmaceutical companies have received significant funding for ADC-related research.

For instance, in October 2022, Mablink Bioscience, raise USD 31 million from Series A funding to build its antibody drug conjugate pipeline. Thus, heavy investments in the R&D of ADCs are expected to improve their availability in the coming years and thus support the demand for ADC contract manufacturing. In September 2021, the U.S. FDA provided accelerated approval for ADC tisotumab vedotin-tftv for treating adult patients with recurrent or metastatic cervical cancer with disease progression or after chemotherapy. Such approvals, in the coming years, are expected to boost the demand for contract manufacturing services for ADC.

Antibody Drug Conjugates Contract Manufacturing Market Report Highlights:

  • Based on condition, the market includes myeloma, lymphoma, breast cancer and others. The myeloma segment led the market with the largest revenue share of 49.61% in 2024. The lymphoma segment is anticipated to witness the fastest CAGR during the forecast period.
  • Based on linker, the market is segmented into cleavable linkers and non-cleavable linkers. The cleavable linkers segment led the market with the largest revenue share of 56.1% in 2024.
  • The antibody drug conjugates contract manufacturing market in North America is expected to witness the fastest CAGR over the forecast period.
  • Asia Pacific antibody drug conjugates contract manufacturing market dominated the market with the largest revenue share of 40.93% in 2024. The regional growth is primarily owing to supportive regulatory reforms, especially in countries such as India & China, and low-cost labor.

Table of Contents

Chapter 1. Research Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Regional Scope
    • 1.1.2. Estimates And Forecast Timeline
  • 1.2. Market Definitions
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased Database
    • 1.4.2. GVR's Internal Database
    • 1.4.3. Secondary Sources
    • 1.4.4. Primary Research
  • 1.5. Information Or Data Analysis
    • 1.5.1. Data Analysis Models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity Flow Analysis
    • 1.7.2. Parent Market Analysis
  • 1.8. List Of Secondary Sources
  • 1.9. List Of Abbreviations
  • 1.10. Objectives
    • 1.10.1. Objective-1
    • 1.10.2. Objective-2
    • 1.10.3. Objective-3

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Antibody Drug Conjugates (ADC) Contract Manufacturing Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/Ancillary Market Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Rising Incidence of Cancer
      • 3.2.1.2. High Cost of Manufacturing ADC and Challenges Associated With Manufacturing Contributing to the Demand for Contract Manufacturing
      • 3.2.1.3. Increasing R&D Activities on ADCs
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. Quality Issues While Outsourcing
      • 3.2.2.2. Limited Outsourcing Opted by Big Biopharma Companies
  • 3.3. Technology Landscape
  • 3.4. Pricing Model Analysis
  • 3.5. Industry Ecosystem Analysis
  • 3.6. Market Analysis Tools
    • 3.6.1. Porter's Five Forces Analysis
    • 3.6.2. PESTEL Analysis
    • 3.6.3. COVID-19 Impact Analysis

Chapter 4. Antibody Drug Conjugates (ADC) Contract Manufacturing Market: Condition Estimates & Trend Analysis

  • 4.1. Antibody Drug Conjugates (ADC) Contract Manufacturing Market, By Condition: Segment Dashboard
  • 4.2. Antibody Drug Conjugates (ADC) Contract Manufacturing Market, By Condition: Movement Analysis
  • 4.3. Antibody Drug Conjugates (ADC) Contract Manufacturing Market Estimates & Forecasts, By Condition, 2018 - 2030 (USD Million)
  • 4.4. Myeloma
    • 4.4.1. Myeloma Market Estimates and Forecasts, 2018 to 2030 (USD Million)
  • 4.5. Lymphoma
    • 4.5.1. Lymphoma Market Estimates and Forecasts, 2018 to 2030 (USD Million)
  • 4.6. Breast Cancer
    • 4.6.1. Breast Cancer Market Estimates and Forecasts, 2018 to 2030 (USD Million)
  • 4.7. Others
    • 4.7.1. Others Market Estimates and Forecasts, 2018 to 2030 (USD Million)

Chapter 5. Antibody Drug Conjugates (ADC) Contract Manufacturing Market: Linker Estimates & Trend Analysis

  • 5.1. Antibody Drug Conjugates (ADC) Contract Manufacturing Market, By Linker: Segment Dashboard
  • 5.2. Antibody Drug Conjugates (ADC) Contract Manufacturing Market, By Linker: Movement Analysis
  • 5.3. Antibody Drug Conjugates (ADC) Contract Manufacturing Market Estimates & Forecasts, By Linker, 2018 - 2030 (USD Million)
  • 5.4. Cleavable Linker
    • 5.4.1. Cleavable Linker Market Estimates and Forecasts, 2018 to 2030 (USD Million)
  • 5.5. Non-Cleavable Linker
    • 5.5.1. Non-Cleavable Linker Market Estimates and Forecasts, 2018 to 2030 (USD Million)

Chapter 6. Antibody Drug Conjugates (ADC) Contract Manufacturing Market: Regional Estimates & Trend Analysis

  • 6.1. Regional Market Share Analysis, 2024 & 2030
  • 6.2. Regional Market Dashboard
  • 6.3. Global Regional Market Snapshot
  • 6.4. North America
    • 6.4.1. North America Market Estimates and Forecasts, 2018 to 2030 (Revenue, USD Million)
    • 6.4.2. U.S.
      • 6.4.2.1. Key Country Dynamics
      • 6.4.2.2. Competitive Scenario
      • 6.4.2.3. Regulatory Framework
      • 6.4.2.4. U.S. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.3. Canada
      • 6.4.3.1. Key Country Dynamics
      • 6.4.3.2. Competitive Scenario
      • 6.4.3.3. Regulatory Framework
      • 6.4.3.4. Canada Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.4. Mexico
      • 6.4.4.1. Key Country Dynamics
      • 6.4.4.2. Competitive Scenario
      • 6.4.4.3. Regulatory Framework
      • 6.4.4.4. Mexico Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5. Europe
    • 6.5.1. Europe Market Estimates and Forecasts, 2018 to 2030 (Revenue, USD Million)
    • 6.5.2. UK
      • 6.5.2.1. Key Country Dynamics
      • 6.5.2.2. Competitive Scenario
      • 6.5.2.3. Regulatory Framework
      • 6.5.2.4. UK Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.3. Germany
      • 6.5.3.1. Key Country Dynamics
      • 6.5.3.2. Competitive Scenario
      • 6.5.3.3. Regulatory Framework
      • 6.5.3.4. Germany Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.4. France
      • 6.5.4.1. Key Country Dynamics
      • 6.5.4.2. Competitive Scenario
      • 6.5.4.3. Regulatory Framework
      • 6.5.4.4. France Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.5. Italy
      • 6.5.5.1. Key Country Dynamics
      • 6.5.5.2. Competitive Scenario
      • 6.5.5.3. Regulatory Framework
      • 6.5.5.4. Italy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.6. Spain
      • 6.5.6.1. Key Country Dynamics
      • 6.5.6.2. Competitive Scenario
      • 6.5.6.3. Regulatory Framework
      • 6.5.6.4. Spain Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.7. Sweden
      • 6.5.7.1. Key Country Dynamics
      • 6.5.7.2. Competitive Scenario
      • 6.5.7.3. Regulatory Framework
      • 6.5.7.4. Sweden Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.8. Denmark
      • 6.5.8.1. Key Country Dynamics
      • 6.5.8.2. Competitive Scenario
      • 6.5.8.3. Regulatory Framework
      • 6.5.8.4. Denmark Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.9. Norway
      • 6.5.9.1. Key Country Dynamics
      • 6.5.9.2. Competitive Scenario
      • 6.5.9.3. Regulatory Framework
      • 6.5.9.4. Norway Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6. Asia Pacific
    • 6.6.1. Asia Pacific Market Estimates and Forecasts, 2018 to 2030 (Revenue, USD Million)
    • 6.6.2. Japan
      • 6.6.2.1. Key Country Dynamics
      • 6.6.2.2. Competitive Scenario
      • 6.6.2.3. Regulatory Framework
      • 6.6.2.4. Japan Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.3. China
      • 6.6.3.1. Key Country Dynamics
      • 6.6.3.2. Competitive Scenario
      • 6.6.3.3. Regulatory Framework
      • 6.6.3.4. China Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.4. India
      • 6.6.4.1. Key Country Dynamics
      • 6.6.4.2. Competitive Scenario
      • 6.6.4.3. Regulatory Framework
      • 6.6.4.4. India Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.5. Thailand
      • 6.6.5.1. Key Country Dynamics
      • 6.6.5.2. Competitive Scenario
      • 6.6.5.3. Regulatory Framework
      • 6.6.5.4. Thailand Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.6. South Korea
      • 6.6.6.1. Key Country Dynamics
      • 6.6.6.2. Competitive Scenario
      • 6.6.6.3. Regulatory Framework
      • 6.6.6.4. South Korea Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.7. Australia
      • 6.6.7.1. Key Country Dynamics
      • 6.6.7.2. Competitive Scenario
      • 6.6.7.3. Regulatory Framework
      • 6.6.7.4. Australia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.7. Latin America
    • 6.7.1. Latin America Market Estimates and Forecasts, 2018 to 2030 (Revenue, USD Million)
    • 6.7.2. Brazil
      • 6.7.2.1. Key Country Dynamics
      • 6.7.2.2. Competitive Scenario
      • 6.7.2.3. Regulatory Framework
      • 6.7.2.4. Brazil Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.7.3. Argentina
      • 6.7.3.1. Key Country Dynamics
      • 6.7.3.2. Competitive Scenario
      • 6.7.3.3. Regulatory Framework
      • 6.7.3.4. Argentina Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.8. MEA
    • 6.8.1. MEA Market Estimates and Forecasts, 2018 to 2030 (Revenue, USD Million)
    • 6.8.2. South Africa
      • 6.8.2.1. Key Country Dynamics
      • 6.8.2.2. Competitive Scenario
      • 6.8.2.3. Regulatory Framework
      • 6.8.2.4. South Africa Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.8.3. Saudi Arabia
      • 6.8.3.1. Key Country Dynamics
      • 6.8.3.2. Competitive Scenario
      • 6.8.3.3. Regulatory Framework
      • 6.8.3.4. Saudi Arabia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.8.4. UAE
      • 6.8.4.1. Key Country Dynamics
      • 6.8.4.2. Competitive Scenario
      • 6.8.4.3. Regulatory Framework
      • 6.8.4.4. UAE Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.8.5. Kuwait
      • 6.8.5.1. Key Country Dynamics
      • 6.8.5.2. Competitive Scenario
      • 6.8.5.3. Regulatory Framework
      • 6.8.5.4. Kuwait Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Market Participant Categorization
    • 7.1.1. Market Leaders
    • 7.1.2. Emerging Players
  • 7.2. Company Market Share/Assessment Analysis, 2024
  • 7.3. Company Profiles
    • 7.3.1. Sterling
      • 7.3.1.1. Company Overview
      • 7.3.1.2. Financial Performance
      • 7.3.1.3. Service Benchmarking
      • 7.3.1.4. Strategic Initiatives
    • 7.3.2. Recipharm AB
      • 7.3.2.1. Company Overview
      • 7.3.2.2. Financial Performance
      • 7.3.2.3. Service Benchmarking
      • 7.3.2.4. Strategic Initiatives
    • 7.3.3. Lonza
      • 7.3.3.1. Company Overview
      • 7.3.3.2. Financial Performance
      • 7.3.3.3. Service Benchmarking
      • 7.3.3.4. Strategic Initiatives
    • 7.3.4. Catalent, Inc.
      • 7.3.4.1. Company Overview
      • 7.3.4.2. Financial Performance
      • 7.3.4.3. Service Benchmarking
      • 7.3.4.4. Strategic Initiatives
    • 7.3.5. Sartorius AG
      • 7.3.5.1. Company Overview
      • 7.3.5.2. Financial Performance
      • 7.3.5.3. Service Benchmarking
      • 7.3.5.4. Strategic Initiatives
    • 7.3.6. Wuxi Biologics
      • 7.3.6.1. Company Overview
      • 7.3.6.2. Financial Performance
      • 7.3.6.3. Service Benchmarking
      • 7.3.6.4. Strategic Initiatives
    • 7.3.7. Samsung Biologics
      • 7.3.7.1. Company Overview
      • 7.3.7.2. Financial Performance
      • 7.3.7.3. Service Benchmarking
      • 7.3.7.4. Strategic Initiatives
    • 7.3.8. Piramal Group (Piramal Pharma Solutions)
      • 7.3.8.1. Company Overview
      • 7.3.8.2. Financial Performance
      • 7.3.8.3. Service Benchmarking
      • 7.3.8.4. Strategic Initiatives
    • 7.3.9. AbbVie, Inc. (AbbVie Contract Manufacturing)
      • 7.3.9.1. Company Overview
      • 7.3.9.2. Financial Performance
      • 7.3.9.3. Service Benchmarking
      • 7.3.9.4. Strategic Initiatives
    • 7.3.10. Merck KGaA
      • 7.3.10.1. Company Overview
      • 7.3.10.2. Financial Performance
      • 7.3.10.3. Service Benchmarking
      • 7.3.10.4. Strategic Initiatives